Fig. 6: Targeting CD37 enhances anti-CD47 efficacy. | Nature Communications

Fig. 6: Targeting CD37 enhances anti-CD47 efficacy.

From: Targeting CD37 promotes macrophage-dependent phagocytosis of multiple cancer cell types and facilitates tumor clearance in mice

Fig. 6

A, B DDMs were treated with Urabrelimab, Naratuximab, or in combination, phagocytosis assay was applied as indicated. DDM donor-derived macrophages. C Mice were treated with Urabrelimab, Naratuximab, or in combination. Live imaging of mice with indicated modifications is presented. D The flux intensity of mice bearing MDA-MB-231 and U251 cells, n = 5 for each group, was shown as a single dot. E The statistical analysis of (D), two-tailed unpaired T-test. F The overall survival of mice with indicated modifications, n = 5 for each group. G The survival analysis of (F), two-tailed Mantel–Cox test. All the experiments were repeated at least three times with similar results.

Back to article page